金河生物: 2025年半年度业绩预告

Performance Forecast - The company expects a net profit of 127.43 million to 141.08 million yuan for the period from January 1, 2025, to June 30, 2025, representing a growth of 40% to 55% compared to the same period last year, where the profit was 91.02 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be between 117.83 million and 131.48 million yuan, an increase of 38.70% to 54.78% from last year's 84.95 million yuan [1] - Basic earnings per share are projected to be between 0.1651 yuan and 0.1828 yuan, compared to 0.1166 yuan in the previous year [1] Reasons for Performance Change - The sales of the veterinary chemical drug segment have continued to improve, with significant growth in both domestic and international markets, particularly in the overseas market [1] - The completion of the company's sixth-phase project has increased production capacity, ensuring supply for both domestic and international markets, which has contributed to higher profits [1] - The agricultural product processing segment has benefited from a decline in the price of corn, positively impacting overall performance [1]